Analyst Gil Blum of Needham reiterated a Buy rating on Autolus Therapeutics, retaining the price target of $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum has given his Buy rating due to a combination of factors including Autolus Therapeutics’ strong second-quarter performance and promising future prospects. The company reported $21 million in sales for its product Aucatzyl, surpassing both the firm’s and market expectations. This robust performance has led to an upward revision of the fiscal year 2025 and 2026 revenue estimates, indicating confidence in the company’s growth trajectory.
Additionally, Autolus has made significant progress in expanding its Activated Treatment Centers (ATCs), increasing from 39 to 46, with a target of reaching 60. Despite facing challenges in the European and UK markets, the company’s strategic advancements and upcoming long-term data presentation at the ACR are viewed positively. These factors collectively support the Buy rating and the $10 target price set by the analyst.
Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Crispr Therapeutics AG, and Nurix Therapeutics. According to TipRanks, Blum has an average return of -3.1% and a 36.94% success rate on recommended stocks.